Vanessa Gulla, MD
Urology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 4 carriers
- Offices
- 4
Offices
4 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
12 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Gulla’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A113017 · Current
Licensed to practise in California · since 2010 · expires 2028-07-31 · University of Vermont College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$138,801
Medicare paid this office $138,801 for 421 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Diagnostic exam of bladder and urethra using an endoscope | 132 | $32,025 | $224 |
| Return visit (30+ min) | 183 | $26,387 | $117 |
| New patient visit (45+ min) | 174 | $24,250 | $139 |
| Botox | 19 | $13,862 | None |
| Exam with injections of chemical for destruction of bladder using an endoscope | 19 | $10,483 | $388 |
See all 12 services
| Diagnostic exam of bladder and urethra using an endoscope | 132 | $32,025 | $224 |
| Return visit (30+ min) | 183 | $26,387 | $117 |
| New patient visit (45+ min) | 174 | $24,250 | $139 |
| Botox | 19 | $13,862 | None |
| Exam with injections of chemical for destruction of bladder using an endoscope | 19 | $10,483 | $388 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 16 | $5,834 | $343 |
| Ultrasound measurement of bladder capacity after voiding | 158 | $2,076 | $12 |
| Biopsy of prostate gland | 11 | $2,043 | $186 |
| New patient visit (30+ min) | 22 | $1,840 | $84 |
| Short return visit (20+ min) | 19 | $1,324 | $70 |
| Electronic assessment of bladder emptying | 27 | $116 | $4 |
| Urinalysis, manual test | 18 | $61 | $3 |
Procedures Medicare counted
| Prostate resection | 1-10 | None |
Who their Medicare patients are
421 Original Medicare patients in 2024. Average age 76 · Under 65 3% · 85 and older 14% · Women 49% · Also on Medicaid 14% · Health risk score 1.36. Above the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 75% · Chronic kidney disease 37% · Diabetes 31% · Coronary heart disease 30% · Depression 21% · Cancer 20% · Atrial fibrillation 20% · Heart failure 17% · COPD 14% · Dementia 10% · Stroke 9%.
The office billed $1,077,101, Medicare allowed $186,351 and paid $138,801; for 3,778 services of 43 kinds; $13,864 of it was for drugs given in the office and $124,937 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 421 | 3,778 | 76 | 1.36 | $1,077,101 | $138,801 |
| 2023 | 493 | 2,595 | 76 | 1.31 | $1,158,620 | $160,718 |
| 2022 | 477 | 1,252 | 76 | 1.34 | $918,886 | $141,590 |
| 2021 | 436 | 1,156 | 75 | 1.29 | $1,008,322 | $122,966 |
| 2020 | 350 | 867 | 74 | 1.48 | $502,767 | $84,331 |
| 2019 | 371 | 891 | 75 | 1.42 | $578,230 | $96,966 |
| 2018 | 391 | 2,155 | 74 | 1.32 | $503,131 | $84,341 |
| 2017 | 394 | 7,270 | 74 | 1.44 | $1,016,662 | $188,782 |
| 2016 | 128 | 427 | 74 | 1.29 | $156,975 | $25,508 |
| 2015 | 255 | 792 | 76 | 1.34 | $159,787 | $45,010 |
| 2014 | 376 | 2,142 | 75 | 1.21 | $367,067 | $122,325 |
| 2013 | 442 | 2,965 | 73 | 1.21 | $607,213 | $177,450 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 17 services
| Diagnostic exam of bladder and urethra using an endoscope | 152 | $38,437 | $233 |
| New patient visit (45+ min) | 212 | $30,676 | $145 |
| Return visit (30+ min) | 136 | $18,794 | $117 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 21 | $9,206 | $400 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 16 | $7,667 | $365 |
| Botox | 20 | $6,021 | None |
| New patient visit (30+ min) | 60 | $5,723 | $95 |
| Long return visit (40+ min) | 39 | $5,700 | $146 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 17 | $5,537 | $326 |
| Insertion of lower leg neurostimulator electrode | 20 | $5,471 | $124 |
| Short return visit (20+ min) | 36 | $3,164 | $81 |
| Ultrasound measurement of bladder capacity after voiding | 218 | $2,768 | $11 |
| Telehealth originating site facility fee | 71 | $2,004 | $22 |
| Telephone medical discussion with physician, 21-30 minutes | 13 | $1,594 | $123 |
| Urinalysis, manual test | 104 | $369 | $3 |
| Imaging of urinary tract following injection of a contrast agent | 11 | $290 | $22 |
| Electronic assessment of bladder emptying | 28 | $127 | $4 |
2022: 13 services
| Diagnostic exam of bladder and urethra using an endoscope | 154 | $43,382 | $241 |
| New patient visit (45+ min) | 217 | $29,985 | $138 |
| Return visit (30+ min) | 117 | $13,609 | $108 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 18 | $9,603 | $400 |
| Long return visit (40+ min) | 40 | $5,691 | $142 |
| New patient visit (30+ min) | 49 | $4,646 | $95 |
| Insertion of lower leg neurostimulator electrode | 24 | $4,448 | $124 |
| Short return visit (20+ min) | 46 | $4,103 | $84 |
| Ultrasound measurement of bladder capacity after voiding | 169 | $2,031 | $11 |
| Telehealth originating site facility fee | 89 | $1,871 | $19 |
| Urinalysis, manual test | 64 | $240 | $3 |
| Electronic assessment of bladder emptying | 30 | $139 | $4 |
| Botox | 16 | $108 | None |
2021: 12 services
| Diagnostic exam of bladder and urethra using an endoscope | 127 | $32,152 | $228 |
| New patient visit (45+ min) | 156 | $22,490 | $144 |
| Return visit (30+ min) | 114 | $14,104 | $107 |
| Long return visit (40+ min) | 46 | $7,924 | $158 |
| Short return visit (20+ min) | 71 | $6,716 | $82 |
| New patient visit (30+ min) | 49 | $5,135 | $105 |
| New patient visit (60+ min) | 18 | $3,806 | $211 |
| Insertion of lower leg neurostimulator electrode | 16 | $2,758 | $131 |
| Telehealth originating site facility fee | 94 | $2,226 | $20 |
| Imaging of urinary tract following injection of a contrast agent | 15 | $411 | $23 |
| Electronic assessment of bladder emptying | 33 | $142 | $4 |
| Urinalysis, manual test | 17 | $59 | $3 |
2020: 9 services
| Diagnostic exam of bladder and urethra using an endoscope | 100 | $22,750 | $205 |
| New patient visit (45+ min) | 144 | $18,767 | $130 |
| Return visit (30+ min) | 94 | $11,508 | $95 |
| Telehealth originating site facility fee | 190 | $4,492 | $21 |
| Short return visit (20+ min) | 67 | $3,980 | $58 |
| Telephone medical discussion with physician, 21-30 minutes | 30 | $3,038 | $101 |
| Telephone medical discussion with physician, 11-20 minutes | 18 | $1,502 | $72 |
| Electronic assessment of bladder emptying | 12 | $63 | $5 |
| Urinalysis, manual test | 14 | $52 | $3 |
2019: 9 services
| Insertion of lower leg neurostimulator electrode | 27 | $25,095 | $127 |
| Return visit (30+ min) | 187 | $19,745 | $82 |
| New patient visit (45+ min) | 132 | $17,227 | $131 |
| Diagnostic exam of bladder and urethra using an endoscope | 79 | $14,187 | $161 |
| Short return visit (20+ min) | 63 | $4,002 | $58 |
| Simple insertion of temporary bladder tube | 13 | $1,929 | $57 |
| Simple bladder irrigation and/or instillation | 11 | $729 | $56 |
| Electronic assessment of bladder emptying | 16 | $84 | $5 |
| Urinalysis, manual test | 12 | $44 | $3 |
2018: 10 services
| Short return visit (20+ min) | 228 | $16,559 | $51 |
| Diagnostic exam of bladder and urethra using an endoscope | 85 | $13,552 | $136 |
| New patient visit (30+ min) | 89 | $7,544 | $85 |
| Return visit (30+ min) | 71 | $6,903 | $86 |
| New patient visit (45+ min) | 52 | $6,855 | $132 |
| Insertion of lower leg neurostimulator electrode | 11 | $4,791 | $109 |
| Ultrasound measurement of bladder capacity after voiding | 22 | $322 | $12 |
| Urinalysis, manual test | 65 | $293 | $3 |
| Automated urinalysis test | 66 | $195 | $3 |
| Electronic assessment of bladder emptying | 14 | $117 | $7 |
2017: 16 services
| Short return visit (20+ min) | 317 | $37,098 | $59 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 15 | $21,949 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 71 | $12,700 | $141 |
| Insertion of lower leg neurostimulator electrode | 13 | $12,458 | $122 |
| New patient visit (45+ min) | 30 | $4,274 | $142 |
| New patient visit (30+ min) | 40 | $3,311 | $83 |
| Simple insertion of temporary bladder tube | 20 | $2,748 | $57 |
| Ultrasound measurement of bladder capacity after voiding | 97 | $2,536 | $18 |
| Return visit (30+ min) | 20 | $2,194 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $2,025 | $61 |
| Automated urinalysis test | 251 | $1,348 | $3 |
| Injection of drug or substance under skin or into muscle | 17 | $917 | $23 |
| Urinalysis, manual test | 156 | $840 | $3 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $586 | $28 |
| Administration of influenza virus vaccine | 11 | $342 | $31 |
| Electronic assessment of bladder emptying | 25 | $267 | $8 |
2016: 7 services
| Diagnostic exam of bladder and urethra using an endoscope | 33 | $5,194 | $157 |
| Short return visit (20+ min) | 76 | $4,496 | $46 |
| New patient visit (30+ min) | 39 | $3,013 | $77 |
| Ultrasound measurement of bladder capacity after voiding | 48 | $1,089 | $15 |
| Urinalysis, manual test | 46 | $232 | $3 |
| Electronic assessment of bladder emptying | 15 | $162 | $10 |
| Automated urinalysis test | 17 | $51 | $3 |
2015: 9 services
| Return visit (30+ min) | 111 | $10,262 | $66 |
| Diagnostic exam of bladder and urethra using an endoscope | 31 | $4,929 | $159 |
| Short return visit (20+ min) | 91 | $4,462 | $46 |
| Insertion of lower leg neurostimulator electrode | 14 | $4,118 | $92 |
| New patient visit (30+ min) | 32 | $2,639 | $82 |
| New patient visit (45+ min) | 12 | $1,609 | $134 |
| Ultrasound measurement of bladder capacity after voiding | 87 | $1,486 | $13 |
| New patient visit (15+ min) | 13 | $535 | $41 |
| Automated urinalysis test | 131 | $486 | $3 |
2014: 17 services
| Return visit (30+ min) | 174 | $23,414 | $82 |
| Insertion of lower leg neurostimulator electrode | 28 | $15,953 | $97 |
| Short return visit (20+ min) | 165 | $15,322 | $57 |
| Diagnostic exam of bladder and urethra using an endoscope | 84 | $14,685 | $161 |
| New patient visit (30+ min) | 116 | $9,900 | $85 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 11 | $5,594 | None |
| Ultrasound measurement of bladder capacity after voiding | 166 | $4,681 | $16 |
| New patient visit (15+ min) | 60 | $3,528 | $59 |
| Simple bladder irrigation and/or instillation | 31 | $3,337 | $68 |
| Automated urinalysis test | 202 | $1,099 | $3 |
| Simple insertion of temporary bladder tube | 13 | $1,053 | $55 |
| Limited ultrasound scan of pelvis | 25 | $829 | $31 |
| Long return visit (40+ min) | 12 | $663 | $55 |
| Injection of drug or substance under skin or into muscle | 15 | $376 | $13 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $320 | $27 |
| Urinalysis, manual test | 52 | $185 | $3 |
| Injection, testosterone cypionate, 1 cc, 200 mg | 12 | $16 | None |
2013: 20 services
| Insertion of lower leg neurostimulator electrode | 48 | $29,837 | $102 |
| Return visit (30+ min) | 184 | $27,941 | $83 |
| Limited ultrasound scan of pelvis | 232 | $24,673 | $67 |
| Diagnostic exam of bladder and urethra using an endoscope | 81 | $13,604 | $162 |
| Short return visit (20+ min) | 128 | $11,410 | $55 |
| Long return visit (40+ min) | 47 | $7,977 | $106 |
| New patient visit (30+ min) | 60 | $4,264 | $71 |
| New patient visit (15+ min) | 81 | $4,157 | $51 |
| Injection of drug or substance under skin or into muscle | 24 | $2,999 | $20 |
| Simple bladder irrigation and/or instillation | 27 | $2,982 | $68 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 16 | $2,810 | $122 |
| Ultrasonic guidance for needle placement | 12 | $2,144 | $165 |
| New patient visit (10+ min) | 63 | $2,106 | $33 |
| Urinalysis, manual test | 284 | $1,726 | $3 |
| Simple insertion of temporary bladder tube | 14 | $1,215 | $55 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 58 | $1,154 | $16 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,076 | $57 |
| Ultrasound scan of pelvic region through rectum | 12 | $819 | $58 |
| Injection, testosterone cypionate, 1 cc, 200 mg | 24 | $604 | None |
| Manual urinalysis test with examination using microscope, non-automated | 79 | $419 | $4 |
Drugs they prescribed that Part D paid
$69,933
Pharmacies billed $69,933 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their Part D prescriptions (17 of 584) in 2024. Above the middle of the specialty; the typical urology clinician is at 2%.
498 generic and fewer than 11 brand-name prescriptions · $69,933 in drug cost · 50 antibiotic prescriptions to 45 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Myrbetriq | 65 | $44,776 | $689 |
| Estradiol | 53 | $2,917 | $55 |
| Tamsulosin | 212 | $2,829 | $13 |
| Finasteride | 112 | $1,571 | $14 |
| Nitrofurantoin Mono-Macro | 29 | $313 | $11 |
See all 7 drugs
| Myrbetriq | 65 | $44,776 | $689 |
| Estradiol | 53 | $2,917 | $55 |
| Tamsulosin | 212 | $2,829 | $13 |
| Finasteride | 112 | $1,571 | $14 |
| Nitrofurantoin Mono-Macro | 29 | $313 | $11 |
| Alfuzosin Hcl Er | 11 | $197 | $18 |
| Hydrocodone-Acetaminophen | 16 | $60 | $4 |
Year by year
| 2024 | 584 | 235 | 3% (17) | None | $69,933 |
| 2023 | 679 | 269 | 2% (16) | 19% | $86,178 |
| 2022 | 698 | 280 | None | 20% | $77,653 |
| 2021 | 602 | 223 | 2% (12) | None | $70,333 |
| 2020 | 640 | 205 | None | 20% | $74,994 |
| 2019 | 1,050 | 239 | None | 18% | $121,426 |
| 2018 | 1,325 | 283 | None | 19% | $163,874 |
| 2017 | 1,231 | 280 | 1% (13) | None | $133,200 |
| 2016 | 274 | 92 | 5% (13) | 9% | $15,049 |
| 2015 | 375 | 107 | None | None | $44,541 |
| 2014 | 664 | 218 | 2% (13) | None | $59,928 |
| 2013 | 662 | 192 | 2% (16) | None | $67,920 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Myrbetriq | 100 | $64,452 | $645 |
| Tamsulosin | 234 | $5,563 | $24 |
| Estradiol | 37 | $3,442 | $93 |
| Finasteride | 140 | $2,509 | $18 |
| Trospium Chloride | 23 | $970 | $42 |
| Nitrofurantoin Mono-Macro | 33 | $505 | $15 |
| Sulfamethoxazole-Trimethoprim | 14 | $64 | $5 |
| Hydrocodone-Acetaminophen | 12 | $41 | $3 |
2022: 11 drugs
| Myrbetriq | 110 | $57,153 | $520 |
| Estradiol | 37 | $4,485 | $121 |
| Tamsulosin | 206 | $3,858 | $19 |
| Tolterodine Tartrate Er | 14 | $2,372 | $169 |
| Finasteride | 109 | $1,917 | $18 |
| Nitrofurantoin Mono-Macro | 47 | $1,282 | $27 |
| Oxybutynin Chloride Er | 17 | $577 | $34 |
| Trospium Chloride | 19 | $507 | $27 |
| Cephalexin | 33 | $165 | $5 |
| Ciprofloxacin | 13 | $74 | $6 |
| Sulfamethoxazole-Trimethoprim | 12 | $46 | $4 |
2021: 8 drugs
| Myrbetriq | 92 | $51,874 | $564 |
| Estradiol | 40 | $4,856 | $121 |
| Tamsulosin | 153 | $2,697 | $18 |
| Finasteride | 105 | $1,525 | $15 |
| Nitrofurantoin Mono-Macro | 46 | $1,071 | $23 |
| Tadalafil | 15 | $923 | $62 |
| Silodosin | 11 | $915 | $83 |
| Cephalexin | 29 | $119 | $4 |
2020: 12 drugs
| Myrbetriq | 93 | $46,464 | $500 |
| Premarin | 16 | $6,383 | $399 |
| Trospium Chloride | 22 | $3,422 | $156 |
| Estradiol | 20 | $3,322 | $166 |
| Tadalafil | 11 | $3,299 | $300 |
| Tamsulosin | 153 | $3,171 | $21 |
| Oxybutynin Chloride Er | 41 | $1,849 | $45 |
| Nitrofurantoin Mono-Macro | 60 | $1,570 | $26 |
| Finasteride | 76 | $1,369 | $18 |
| Cephalexin | 32 | $172 | $5 |
| Penicillin V | 13 | $92 | $7 |
| Ciprofloxacin | 11 | $53 | $5 |
2019: 17 drugs
| Myrbetriq | 120 | $58,307 | $486 |
| Vesicare | 21 | $8,999 | $429 |
| Tamsulosin | 300 | $7,109 | $24 |
| Trospium Chloride | 42 | $5,845 | $139 |
| Tadalafil | 15 | $5,565 | $371 |
| Oxybutynin Chloride Er | 109 | $5,326 | $49 |
| Finasteride | 138 | $3,390 | $25 |
| Estradiol | 11 | $2,418 | $220 |
| Silodosin | 24 | $2,311 | $96 |
| Dutasteride | 15 | $2,156 | $144 |
| Nitrofurantoin Mono-Macro | 54 | $1,596 | $30 |
| Potassium Citrate Er | 11 | $1,398 | $127 |
| Oxybutynin Chloride | 34 | $813 | $24 |
| Alfuzosin Hcl Er | 12 | $378 | $32 |
| Sulfamethoxazole-Trimethoprim | 13 | $72 | $6 |
| Cephalexin | 11 | $67 | $6 |
| Ciprofloxacin | 14 | $61 | $4 |
2018: 23 drugs
| Myrbetriq | 50 | $29,646 | $593 |
| Vesicare | 35 | $20,031 | $572 |
| Cialis | 36 | $19,417 | $539 |
| Elmiron | 15 | $14,495 | $966 |
| Tamsulosin | 415 | $10,968 | $26 |
| Premarin | 12 | $5,059 | $422 |
| Toviaz | 15 | $4,726 | $315 |
| Oxybutynin Chloride Er | 80 | $4,719 | $59 |
| Tolterodine Tartrate Er | 22 | $4,540 | $206 |
| Finasteride | 231 | $3,896 | $17 |
| Estradiol | 12 | $2,558 | $213 |
| Trospium Chloride | 32 | $2,542 | $79 |
| Potassium Citrate Er | 15 | $2,382 | $159 |
| Dutasteride | 15 | $2,165 | $144 |
| Nitrofurantoin Mono-Macro | 46 | $1,871 | $41 |
| Oxybutynin Chloride | 47 | $1,263 | $27 |
| Alfuzosin Hcl Er | 20 | $476 | $24 |
| Terazosin | 18 | $300 | $17 |
| Testosterone Cypionate | 12 | $275 | $23 |
| Amitriptyline | 24 | $234 | $10 |
| Cephalexin | 25 | $136 | $5 |
| Ciprofloxacin | 24 | $117 | $5 |
| Sulfamethoxazole-Trimethoprim | 12 | $49 | $4 |
2017: 20 drugs
| Myrbetriq | 68 | $32,662 | $480 |
| Vesicare | 54 | $21,698 | $402 |
| Tamsulosin | 392 | $11,319 | $29 |
| Elmiron | 17 | $11,217 | $660 |
| Cialis | 18 | $10,292 | $572 |
| Rapaflo | 24 | $8,184 | $341 |
| Tolterodine Tartrate Er | 39 | $7,514 | $193 |
| Finasteride | 234 | $3,650 | $16 |
| Oxybutynin Chloride Er | 40 | $2,309 | $58 |
| Potassium Citrate Er | 13 | $2,259 | $174 |
| Nitrofurantoin Mono-Macro | 40 | $1,221 | $31 |
| Dutasteride | 17 | $1,116 | $66 |
| Trospium Chloride | 11 | $885 | $80 |
| Oxybutynin Chloride | 28 | $582 | $21 |
| Alfuzosin Hcl Er | 14 | $240 | $17 |
| Cephalexin | 29 | $199 | $7 |
| Ciprofloxacin | 30 | $178 | $6 |
| Terazosin | 18 | $170 | $9 |
| Sulfamethoxazole-Trimethoprim | 17 | $90 | $5 |
| Hydrocodone-Acetaminophen | 11 | $57 | $5 |
2016: 5 drugs
| Vesicare | 14 | $4,611 | $329 |
| Tamsulosin | 94 | $2,391 | $25 |
| Oxybutynin Chloride | 32 | $1,167 | $36 |
| Finasteride | 39 | $515 | $13 |
| Cephalexin | 20 | $52 | $3 |
2015: 6 drugs
| Vesicare | 77 | $24,042 | $312 |
| Myrbetriq | 11 | $3,563 | $324 |
| Tamsulosin | 79 | $2,432 | $31 |
| Finasteride | 81 | $1,389 | $17 |
| Oxybutynin Chloride | 23 | $466 | $20 |
| Ciprofloxacin | 11 | $48 | $4 |
2014: 14 drugs
| Vesicare | 111 | $28,087 | $253 |
| Rapaflo | 26 | $4,085 | $157 |
| Avodart | 16 | $3,518 | $220 |
| Estrace | 20 | $3,367 | $168 |
| Toviaz | 14 | $3,009 | $215 |
| Tolterodine Tartrate Er | 11 | $2,627 | $239 |
| Tamsulosin | 113 | $2,141 | $19 |
| Oxybutynin Chloride | 36 | $1,288 | $36 |
| Finasteride | 67 | $961 | $14 |
| Nitrofurantoin Mono-Macro | 36 | $614 | $17 |
| Cephalexin | 67 | $227 | $3 |
| Ciprofloxacin | 42 | $196 | $5 |
| Hydrocodone-Acetaminophen | 13 | $88 | $7 |
| Sulfamethoxazole-Trimethoprim | 11 | $45 | $4 |
2013: 15 drugs
| Vesicare | 159 | $36,580 | $230 |
| Premarin | 34 | $6,727 | $198 |
| Estrace | 32 | $4,791 | $150 |
| Enablex | 17 | $2,955 | $174 |
| Rapaflo | 12 | $1,950 | $162 |
| Jalyn | 12 | $1,799 | $150 |
| Tamsulosin | 77 | $1,363 | $18 |
| Nitrofurantoin Mono-Macro | 41 | $1,355 | $33 |
| Oxybutynin Chloride Er | 16 | $1,187 | $74 |
| Oxybutynin Chloride | 50 | $1,105 | $22 |
| Finasteride | 29 | $738 | $25 |
| Ciprofloxacin | 46 | $257 | $6 |
| Cephalexin | 29 | $239 | $8 |
| Sulfamethoxazole-Trimethoprim | 25 | $116 | $5 |
| Hydrocodone-Acetaminophen | 16 | $109 | $7 |
Money from drug and device companies
$20 in 2025
| 2025 | 1 | 1 | None | $20 |
| 2024 | 1 | 1 | None | $11 |
| 2023 | 3 | 3 | None | $140 |
| 2022 | 1 | 1 | None | $12 |
| 2020 | 1 | 1 | None | $24 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | Bulkamid | $20 | 1 payment
|
See the published payment
| Boston Scientific | Meals · 2025-06-03 | Bulkamid | $20 |
See earlier years (2024, 2023, 2022, 2020)
2024: $11
| Laborie Medical Technologies | Optilume Bph Drug Coated Balloon Catheter | $11 | 1 payment
|
2023: $140
| Medtronic | Interstim | $95 | 1 payment
|
| Olympus America | Cysto-Nephro Videoscope | $23 | 1 payment
|
| Valencia Technologies | Ecoin Device Kit | $21 | 1 payment
|
2022: $12
| Ambu | None | $12 | 1 payment
|
2020: $24
| Boston Scientific | General - Bph | $24 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1376648279
- Licence
- CA A113017, NH RT 1383California A113017: Current · expires 2028-07-31
- Trained
- Geisel School of Medicine at Dartmouth, 2010
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Urology (208800000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-09-14
- NPI last updated
- 2024-03-14
- NPI record certified
- 2024-03-14
This is when the NPI record was last certified, not a medical board exam.